Here's Exactly What It Will Take for Madrigal Pharmaceuticals Stock to Take Off
MASH cirrhosis could significantly expand Rezdiffra's addressable market. Madrigal's developing pipeline could reduce its dependence on Rezdiffra.
MDGL - Madrigal Pharmaceuticals, Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$677.00
DETAILS
HIGH:
$962.00
LOW:
$542.00
MEDIAN:
$649.00
CONSENSUS:
$677.00
UPSIDE:
26.84%
Stock News
Allworth Financial LP Buys New Position in Madrigal Pharmaceuticals, Inc. $MDGL
Allworth Financial LP bought a new position in shares of Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) in the second quarter, according to the company in its most recent filing with the SEC. The fund bought 3,562 shares of the biopharmaceutical company's stock, valued at approximately $1,913,000. Several other hedge funds and other institutional investors
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
CONSHOHOCKEN, Pa., Aug. 20, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that it granted equity awards on August 15, 2026 to 13 new non-executive employees as equity inducement awards under the terms of Madrigal's 2025 Inducement Plan. The equity awards were approved by Madrigal's independent Compensation Committee in accordance with Nasdaq Listing Rule 5635(c)(4).
Madrigal’s Rezdiffra Hits $1.3B Run Rate as MASH Pipeline Expands
Madrigal Pharmaceuticals (NASDAQ: MDGL) said Rezdiffra continued to post strong commercial growth in the second quarter of 2026, while the company expanded its development pipeline around the MASH therapy and prepared for several potential clinical catalysts. Speaking at a Canaccord Genuity event, Chief Financial Officer Mardi Dier said the company reported $364 million in second-quarter revenue,
Madrigal's Rezdiffra Hits $1.3B Run Rate as MASH Pipeline Expands
Madrigal Pharmaceuticals NASDAQ: MDGL said Rezdiffra continued to post strong commercial growth in the second quarter of 2026, while the company expanded its development pipeline around the MASH therapy and prepared for several potential clinical catalysts.
John Paulson's Top Q2 2026 Move: Exiting Agnico Eagle Mines Ltd at a -5.11% Portfolio Impact
Paulson and Co. reshapes portfolio with a major gold stock exit and a new tech positionJohn Paulson (Trades, Portfolio), President and Portfolio Manager of Paulso
Madrigal Appoints John C. Reed, M.D.
CONSHOHOCKEN, Pa., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced it has appointed John C.
Madrigal Pharmaceuticals, Inc. (MDGL) Presents at Canaccord Genuity's 46th Annual Growth Conference Transcript
Madrigal Pharmaceuticals, Inc. (MDGL) Presents at Canaccord Genuity's 46th Annual Growth Conference Transcript
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
CONSHOHOCKEN, Pa., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that it granted equity awards on August 1, 2026 to ten new non-executive employees as equity inducement awards under the terms of Madrigal's 2025 Inducement Plan.
Madrigal Pharmaceuticals to Participate in the Canaccord Genuity 45th Annual Growth Conference
CONSHOHOCKEN, Pa., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) announced today that the company will participate in the Canaccord Genuity 46th Annual Growth Conference on Tuesday, Aug. 11, 2026 at 12:00 P.M. EDT.
Here Are Tuesday’s Top Wall Street Analyst Research Calls: Apple, CoreWeave, eBay, Exxon Mobil, Intuit, Nebius Group, Palantir Technologies, SK hynix, and More
Wall Street wasted no time Monday, sending the Nasdaq surging past 25,900 while analysts took aim at some of the market's biggest names with fresh upgrades, downgrades, and new coverage that could reshape how investors approach the week ahead.
MDGL Stock Down Despite Q2 Beat, MASH Drug Drives Top-Line Y/Y Growth
Madrigal beats Q2 estimates as Rezdiffra sales lift revenues 71% year over year, but shares fall as investors weigh slower commercial growth.
Madrigal Pharmaceuticals Q2 Earnings Call Highlights
Madrigal Pharmaceuticals NASDAQ: MDGL reported second-quarter 2026 net sales of $364.3 million for Rezdiffra, up 71% from a year earlier, as the company continued to expand the number of patients receiving its treatment for metabolic dysfunction-associated steatohepatitis, or MASH.
Madrigal Pharmaceuticals, Inc. (MDGL) Q2 2026 Earnings Call Transcript
Madrigal Pharmaceuticals, Inc. (MDGL) Q2 2026 Earnings Call Transcript
Madrigal (MDGL) Reports Q2 Loss, Beats Revenue Estimates
Madrigal (MDGL) came out with a quarterly loss of $1.99 per share versus the Zacks Consensus Estimate of a loss of $2.55. This compares to a loss of $1.9 per share a year ago.
Madrigal Pharmaceuticals Reports Second-Quarter 2026 Financial Results and Provides Corporate Updates
CONSHOHOCKEN, Pa., July 30, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today reports second-quarter 2026 financial results and provides corporate updates.
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
CONSHOHOCKEN, Pa., July 21, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that it granted equity awards on July 15, 2026 to ten new non-executive employees as equity inducement awards under the terms of Madrigal's 2025 Inducement Plan. The equity awards were approved by Madrigal's independent Compensation Committee in accordance with Nasdaq Listing Rule 5635(c)(4).
Madrigal Pharmaceuticals to Release Second-Quarter 2026 Financial Results and Host Webcast on July 30, 2026
CONSHOHOCKEN, Pa., July 16, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) announced today that it will release its second-quarter 2026 financial results on Thursday, July 30, 2026, prior to the open of the U.S. financial markets.
Madrigal Pharmaceuticals Announces Three New Resmetirom Patents, Strengthening IP Portfolio
Received two new U.S. Rezdiffra ® (resmetirom) patents in F2/F3; both patents will be listed in the FDA's Orange Book Received new U.S. resmetirom patent directed to a method of administering resmetirom to treat well-compensated cirrhosis (F4c) CONSHOHOCKEN, Pa., July 13, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that the United States Patent and Trademark Office (USPTO) issued three new resmetirom patents.
3 Under-the-Radar Stocks to Buy and Hold
These three biotechs are posting strong revenue growth. Brand-new launches and label expansions should help them improve their lineups.
Price Targets
Madrigal upgraded to Outperform from Peer Perform at Wolfe Research
$605.00
(was $482.00)
Wolfe Research
Madrigal Pharmaceuticals (MDGL) PT Lowered to $962 at BarclaysMember Login
$962.00
(was $493.11)
Barclays
Madrigal Pharmaceuticals price target raised to $587 from $578 at Canaccord
$587.00
(was $538.80)
Canaccord Genuity
Madrigal Pharmaceuticals initiated with an Overweight at Wells Fargo
$685.00
(was $544.51)
Wells Fargo
Madrigal Pharmaceuticals (MDGL) PT Lowered to $542 at BofA Securities
$542.00
(was $471.32)
Morgan Stanley
Madrigal Pharmaceuticals price target raised to $709 from $640 at Truist
$709.00
(was $513.30)
Truist Financial
Madrigal Pharmaceuticals price target lowered to $649 from $652 at Evercore ISI
$649.00
(was $539.73)
Evercore ISI
Madrigal Pharmaceuticals price target lowered to $578 from $587 at Canaccord
$578.00
(was $539.73)
Canaccord Genuity
Madrigal Pharmaceuticals initiated with an Overweight at Barclays
$964.00
(was $500.39)
Barclays
Goldman Sachs Reiterates Buy Rating on Madrigal Pharmaceuticals (MDGL)
$571.00
(was $493.90)
Andrea Tan
·
Goldman Sachs
Wolfe downgrades Madrigal Pharmaceuticals to Peer Perform on valuation
$579.00
(was $588.40)
Andy Chen
·
Wolfe Research
Madrigal Pharmaceuticals (MDGL) PT Raised to $900 as Piper Sandler Recommends Buy
$900.00
(was $588.81)
Yasmeen Rahimi
·
Piper Sandler
Madrigal Pharmaceuticals price target raised to $900 from $540 at Piper Sandler
$900.00
(was $544.41)
UBS
Madrigal price target raised to $620 from $568 at H.C. Wainwright
$620.00
(was $558.61)
H.C. Wainwright
Madrigal Pharmaceuticals price target raised to $650 from $600 at Oppenheimer
$650.00
(was $568.01)
Jay Olson
·
Oppenheimer
Madrigal Pharmaceuticals price target raised to $640 from $580 at Truist
$640.00
(was $555.60)
Truist Financial
Madrigal Pharmaceuticals price target raised to $527 from $485 at Citizens JMP
$527.00
(was $444.64)
JMP Securities
Madrigal Pharmaceuticals price target raised to $540 from $400 at Piper Sandler
$540.00
(was $437.10)
Piper Sandler
Madrigal Pharmaceuticals initiated with a Buy at Truist
$580.00
(was $437.10)
Truist Financial
Madrigal Pharmaceuticals price target raised to $590 from $500 at Oppenheimer
$590.00
(was $428.30)
Jay Olson
·
Oppenheimer